Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.
Alemtuzumab is a powerful lymphocyte depleting antibody currently being evaluated in solid organ transplantation. This paper describes 5-year results of a single center study of alemtuzumab as induction in renal transplantation. Thirty-three renal transplant recipients received 20 mg alemtuzumab on...
| প্রধান লেখক: | , , , , , , , , , , , |
|---|---|
| বিন্যাস: | Journal article |
| ভাষা: | English |
| প্রকাশিত: |
2005
|
| _version_ | 1826274802472583168 |
|---|---|
| author | Watson, C Bradley, J Friend, P Firth, J Taylor, C Bradley, JR Smith, K Thiru, S Jamieson, N Hale, G Waldmann, H Calne, R |
| author_facet | Watson, C Bradley, J Friend, P Firth, J Taylor, C Bradley, JR Smith, K Thiru, S Jamieson, N Hale, G Waldmann, H Calne, R |
| author_sort | Watson, C |
| collection | OXFORD |
| description | Alemtuzumab is a powerful lymphocyte depleting antibody currently being evaluated in solid organ transplantation. This paper describes 5-year results of a single center study of alemtuzumab as induction in renal transplantation. Thirty-three renal transplant recipients received 20 mg alemtuzumab on day 0 and 1, followed by half-dose cyclosporin monotherapy (trough concentration 75-125 ng/mL) from day 3. They were compared in a retrospective contemporaneous-controlled manner with 66 kidney transplant recipients transplanted in the same period and center who received conventional immunosuppression with cyclosporin, azathioprine and prednisolone. In the alemtuzumab group 12% of recipients died compared to 17% in the control group (p = 0.48); likewise graft loss was similar in both groups (21% vs. 26%, respectively, p = 0.58). Incidence of acute rejection was also comparable at 5 years (31.5% vs. 33.6%), although the pattern of rejection was different with 14% patients in the alemtuzumab group experiencing rejection over 1 year post-transplant compared to none in the control group. There was no significant difference between groups in terms of infection or serious adverse events. While acknowledging the limitations of a relatively small single-center study, results suggest that alemtuzumab induction allowed satisfactory long-term patient and graft survival equivalent to that seen with standard triple immunosuppression, while avoiding steroid therapy. |
| first_indexed | 2024-03-06T22:48:58Z |
| format | Journal article |
| id | oxford-uuid:5e291ad5-f0b5-48eb-a6f0-f90b5d785204 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T22:48:58Z |
| publishDate | 2005 |
| record_format | dspace |
| spelling | oxford-uuid:5e291ad5-f0b5-48eb-a6f0-f90b5d7852042022-03-26T17:38:49ZAlemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:5e291ad5-f0b5-48eb-a6f0-f90b5d785204EnglishSymplectic Elements at Oxford2005Watson, CBradley, JFriend, PFirth, JTaylor, CBradley, JRSmith, KThiru, SJamieson, NHale, GWaldmann, HCalne, RAlemtuzumab is a powerful lymphocyte depleting antibody currently being evaluated in solid organ transplantation. This paper describes 5-year results of a single center study of alemtuzumab as induction in renal transplantation. Thirty-three renal transplant recipients received 20 mg alemtuzumab on day 0 and 1, followed by half-dose cyclosporin monotherapy (trough concentration 75-125 ng/mL) from day 3. They were compared in a retrospective contemporaneous-controlled manner with 66 kidney transplant recipients transplanted in the same period and center who received conventional immunosuppression with cyclosporin, azathioprine and prednisolone. In the alemtuzumab group 12% of recipients died compared to 17% in the control group (p = 0.48); likewise graft loss was similar in both groups (21% vs. 26%, respectively, p = 0.58). Incidence of acute rejection was also comparable at 5 years (31.5% vs. 33.6%), although the pattern of rejection was different with 14% patients in the alemtuzumab group experiencing rejection over 1 year post-transplant compared to none in the control group. There was no significant difference between groups in terms of infection or serious adverse events. While acknowledging the limitations of a relatively small single-center study, results suggest that alemtuzumab induction allowed satisfactory long-term patient and graft survival equivalent to that seen with standard triple immunosuppression, while avoiding steroid therapy. |
| spellingShingle | Watson, C Bradley, J Friend, P Firth, J Taylor, C Bradley, JR Smith, K Thiru, S Jamieson, N Hale, G Waldmann, H Calne, R Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years. |
| title | Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years. |
| title_full | Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years. |
| title_fullStr | Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years. |
| title_full_unstemmed | Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years. |
| title_short | Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years. |
| title_sort | alemtuzumab campath 1h induction therapy in cadaveric kidney transplantation efficacy and safety at five years |
| work_keys_str_mv | AT watsonc alemtuzumabcampath1hinductiontherapyincadaverickidneytransplantationefficacyandsafetyatfiveyears AT bradleyj alemtuzumabcampath1hinductiontherapyincadaverickidneytransplantationefficacyandsafetyatfiveyears AT friendp alemtuzumabcampath1hinductiontherapyincadaverickidneytransplantationefficacyandsafetyatfiveyears AT firthj alemtuzumabcampath1hinductiontherapyincadaverickidneytransplantationefficacyandsafetyatfiveyears AT taylorc alemtuzumabcampath1hinductiontherapyincadaverickidneytransplantationefficacyandsafetyatfiveyears AT bradleyjr alemtuzumabcampath1hinductiontherapyincadaverickidneytransplantationefficacyandsafetyatfiveyears AT smithk alemtuzumabcampath1hinductiontherapyincadaverickidneytransplantationefficacyandsafetyatfiveyears AT thirus alemtuzumabcampath1hinductiontherapyincadaverickidneytransplantationefficacyandsafetyatfiveyears AT jamiesonn alemtuzumabcampath1hinductiontherapyincadaverickidneytransplantationefficacyandsafetyatfiveyears AT haleg alemtuzumabcampath1hinductiontherapyincadaverickidneytransplantationefficacyandsafetyatfiveyears AT waldmannh alemtuzumabcampath1hinductiontherapyincadaverickidneytransplantationefficacyandsafetyatfiveyears AT calner alemtuzumabcampath1hinductiontherapyincadaverickidneytransplantationefficacyandsafetyatfiveyears |